Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

October 11, 2017

CAR T-cells Targeting CD20-positive Non-Hodgkin’s Lymphoma Safe and Effective, Long-term Study Shows

News

A long-term follow-up study of immunotherapy with CAR T-cells in patients with B-cell non-Hodgkin’s lymphoma with CD20-carrying B-cells show the approach is similar in effectiveness and safety to the more ... Read more

October 5, 2017

Lymphoma Scare Turned Out to Be a Reaction to Tattoo Ink, Case Study Reports

News

Tattoo ink can generate a condition that mimics lymphoma, doctors at the Royal Prince Alfred Hospital in Australia discovered. A 30-year-old woman showed many of the signs of lymphoma. But ... Read more

October 4, 2017

FDA Gives Adcetris-Chemo Combo Breakthrough Therapy Status as First-Line Hodgkin Lymphoma Therapy

News

The U.S. Food and Drug Administration has granted Adcetris (brentuximab vedotin) Breakthrough Therapy Designation as a treatment with chemotherapy for patients with previously untreated advanced classical Hodgkin lymphoma. The designation, awarded ... Read more

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance therapy. ... Read more

September 18, 2017

Bayer Presents Copanlisib Combination Trials at Scientific Meeting

News

Two Phase 3 trials will assess the potential of Bayer’s copanlisib in combination with other treatment in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma, based on positive data from a ... Read more

September 15, 2017September 15, 2017

FDA Approves Bayer’s Aliqopa for Relapsed Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Bayer’s Aliqopa (copanlisib) for patients with follicular lymphoma who have relapsed after at least two earlier therapies. The agency granted Aliqopa an accelerated ... Read more

September 7, 2017

Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL

News

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced. ... Read more

September 5, 2017

FDA Approves Mylotarg for Adults and Children with AML

News

The U.S. Food and Drug Administration has approved Pfizer’s Mylotarg (gemtuzumab ozogamicin) for adults and children with acute myeloid leukemia (AML) whose cancer carries the CD33 marker. In adults, Mylotarg ... Read more

August 31, 2017September 1, 2017

FDA Approves First-Ever CAR T-Cell Therapy, Kymriah, for Young B-Cell ALL Patients

News

In what is described as a historical decision, the U.S. Food and Drug Administration (FDA) has approved the first gene therapy-based cancer treatment in the United States. The FDA approved Novartis’ ... Read more

August 22, 2017

Vorinostat Might Reduce Stem Cell Transplant Rejection in High-risk Patients

News

Adding vorinostat to the standard treatment used during high-risk stem cell transplants might reduce rates of acute transplant rejection, according to a small Phase 2 trial. Since the study also ... Read more